BioSpace News Archive

VBL Therapeutics (Nasdaq: VBLT) announced today that the first two patients have been enrolled in the Phase 2 clinical trial of VB-111 in combination with nivolumab (Opdivo®), an immune checkpoint inhibitor, for the treatment of metastatic colorectal cancer.

Dr. Edward Strong, the geneticist who co-founded and served as CEO of MedGenomics, Inc., has been named Scientific Director of iAssay, Inc.

Recently completed tests in the United States at the Colorado State University Biological Safety Level 3 (BSL-3) research laboratory have demonstrated, for the first time, that the surface material of a new face mask can eliminate more than 99.99 percent of the SARS-CoV-2 virus strain within 30 minutes.

Helio Health (formerly known as Laboratory for Advanced Medicine), an AI-driven healthcare company focused on commercializing early cancer detection tests from a simple blood draw, today announced a multicenter collaboration with the Icahn School of Medicine at Mount Sinai.

Accuray Incorporated announced that Joshua H. Levine, president and chief executive officer and Shig Hamamatsu, chief financial officer will present at the fourth annual Lake Street Capital Markets Best Ideas Growth Conference on Thursday, September 17, 2020.

The expanded clinical research offering will see Europital support clients as a full service CRO in over 40 countries from IND through to commercial launch.

Lyra Therapeutics, Inc., (Nasdaq: LYRA), today announced the presentation of data showing that LYR-210 demonstrated a significant reduction of sinonasal Type 2 inflammation in surgically naïve patients with chronic rhinosinusitis (CRS)

Micro-Tech Endoscopy recently expanded its presence in the Infection Prevention market with the launch of the Jacket Disposable Biopsy Valve.

ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that the Compensation Committee of ANI’s Board of Directors granted a non-qualified inducement stock option to purchase an aggregate of 179,643 shares of ANI’s common stock to Nikhil Lalwani, President and Chief Executive Officer of ANI, effective September 8, 2020.

Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 11,666,667 shares of its common stock at a public offering price of $30.00 per share